Literature DB >> 29655962

Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.

Sabrina Prommersberger1, Hardikkumar Jetani2, Sophia Danhof2, Razieh Monjezi2, Thomas Nerreter2, Julia Beckmann2, Herrmann Einsele2, Michael Hudecek2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29655962     DOI: 10.1016/j.retram.2018.03.006

Source DB:  PubMed          Journal:  Curr Res Transl Med        ISSN: 2452-3186            Impact factor:   4.513


× No keyword cloud information.
  5 in total

Review 1.  Cell-based immunotherapy approaches for multiple myeloma.

Authors:  Katharina Kriegsmann; Mark Kriegsmann; Martin Cremer; Michael Schmitt; Peter Dreger; Hartmut Goldschmidt; Carsten Müller-Tidow; Michael Hundemer
Journal:  Br J Cancer       Date:  2018-12-06       Impact factor: 7.640

Review 2.  Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.

Authors:  Weiqi Yan; Zhuojun Liu; Jia Liu; Yuanshi Xia; Kai Hu; Jian Yu
Journal:  Biomed Res Int       Date:  2020-10-01       Impact factor: 3.411

3.  Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia.

Authors:  Guoqiang Lin; Yanming Zhang; Lei Yu; Depei Wu
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

4.  CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy.

Authors:  Jan David Beck; Matthias Birtel; Erik Haefner; Isabell Sofia Keil; Daniel Reidenbach; Nadja Salomon; Ikra Gizem Yildiz; Mustafa Diken
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

Review 5.  Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.

Authors:  Marius Maucher; Micha Srour; Sophia Danhof; Hermann Einsele; Michael Hudecek; Ibrahim Yakoub-Agha
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.